Teriparatide is a synthetic form of the first 34 amino acids of human parathyroid hormone (PTH), used as an anabolic agent to treat osteoporosis.  Its primary benefits include:
Stimulates new bone formation: Teriparatide activates osteoblasts (bone-forming cells), increasing bone mineral density (BMD), particularly in the lumbar spine and hip, leading to stronger bones and reduced fracture risk. 
Reduces fracture risk: Clinical trials, including the pivotal Fracture Prevention Trial, showed a 65% reduction in vertebral fractures and a 53% reduction in nonvertebral fractures in postmenopausal women with osteoporosis. 
Improves bone microarchitecture: It enhances trabecular thickness and connectivity, improving overall bone strength and structure.
Effective across patient groups: Proven beneficial in postmenopausal women, men with primary or hypogonadal osteoporosis, and individuals with glucocorticoid-induced osteoporosis. 
Supports implant integration: Promotes bone formation around orthopedic implants, improving osseointegration and stability. 
Enhances fracture healing: Shows potential as an adjunct in treating osteoporotic fractures, especially when combined with other therapies. 
These benefits are achieved through intermittent daily subcutaneous dosing, with treatment limited to 24 months due to safety considerations, including a potential risk of osteosarcoma observed in animal studies.